Pharmacokinetics of rituximab and its clinical use: Thought for the best use?

Critical Reviews in Oncology/Hematology

Volumn 62, Issue 1, 2007, Pages 43-52

  Cartron, Guillaume ^a,b   Blasco, Hélène ^c   Paintaud, Gilles ^a,c   Watier, Hervé ^a,c   Le Guellec, Chantal ^c  

^a UNIVERSITÉ DE TOURS   (France)

^b CENTRE JEAN BERNARD   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Pharmacokinetics; Rituximab; Treatment optimisation

Indexed keywords

METHOTREXATE; RITUXIMAB;

AUTOIMMUNE DISEASE; CANCER REGRESSION; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG USE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 33847257777     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.09.004     Document Type: Review

References (63)

1. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
2. Cartron G., Watier H., Golay L., and Solal-Céligny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004) 2635-2642
3. Watier H. Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. Expert Opin Biol Ther 5 (2005) S29-S36
4. Colombat P., Salles G., Brousse N., et al. Rituximab (anti-CD20 monoclonal antibody) as first-line therapy of follicular lymphoma patients with low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101-106
5. Hainsworth J.D., Burris III H.A., Morrissey L.H., et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95 (2000) 3052-3056
6. Witzig T.E., Vukov A.M., Habermann T.M., et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phae II trial in the North Central Cancer Treatment Group. J Clin Oncol 23 (2005) 1103-1108
7. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
8. Grillo-Lopez A.J. Rituximab (Rituxan/MabThera): the first decade (1993-2003). Expert Rev Anticancer Ther 3 (2003) 767-779
9. Berinstein N.L., Grillo-Lopez A.J., White C.A., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9 (1998) 995-1001
10. Manshouri T., Do K.A., Wang X., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101 (2003) 2507-2513
11. Tobinai K., Igarashi T., Itoh K., et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15 (2004) 821-830
12. Igarashi T., Kobayashi Y., Ogura M., et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 13 (2002) 928-943
13. Anolik J.H., Campbell D., Felgar R.E., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48 (2003) 455-459
14. Maloney D.G., Liles T.M., Czerwinski D.K., Rosenberg J., Grillo-Lopez A., and Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84 (1994) 2457-2466
15. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15 (1997) 3266-3274
16. Coiffier B., Haioun C., Ketterer N., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92 (1998) 1927-1932
17. O'Brien S.M., Kantarjina H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J Clin Oncol 19 (2001) 2165-2170
18. Aviles A., Leon M.I., Diaz-Maqueo J.C., Garcia E.L., Cleto S., and Neri N. Rituximab in the treatment of refractory follicular lymphoma-six doses are better than four. J Hematother Stem Cell Res 10 (2001) 313-316
19. Bremer K. Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non Hodgkin's lymphoma: a phase II study. Anti-Cancer Drugs 14 (2003) 809-815
20. Piro L.D., White C.A., Grillo-Lopez A.J., et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10 (1999) 655-661
21. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using thrice weekly dosing schedule in B-cell chronic lymphocytoc leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001) 2153-2164
22. Coiffier B., Lepage E., Brière J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
23. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 (2005) 3725-3732
24. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared to CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
25. Czuczman M.S., Grillo-Lopez A.J., White C.A., et al. Treatment of patients with low grade B-cell lymphoma with combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 (1999) 268-276
26. Ogura M., Morishima Y., Kagami Y., et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 97 (2006) 305-312
27. Ghielmini M., Schmitz S.F.H., Cogliatti S.B., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with standard weekly X4 schedule. Blood 103 (2004) 4416-4423
28. Hochster H.S., Weller E., Gascoyne R.D., et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106 (2005) [abstract 349]
29. Habermann T.M., Weller E., Morrisson V.A., et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood 104 (2004) 40a [abstract 127]
30. Hainsworth J.D., Litchy S., Burris H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 4261-4267
31. Brugger W., Hirsh J., Grünebach F., et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15 (2004) 1691-1698
32. Van Oers M.H.J., Van Glabbeke, Teodorovic M., et al. Chimeric anti-CD20 monoclonal antibody (Rituximab; MabThera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: final analysis of phase III randomized intergroup clinical trial. Blood 106 (2005) [abstract 353]
33. Gordan L.N., Grow W.B., Pusateri A., Douglas V., Mendenhall N.P., and Lynch J.W. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23 (2005) 1096-1102
34. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
35. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus. Arthritis Rheum 50 (2004) 2580-2589
36. Cooper N., Stasi R., Cunnigham-Rundles S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125 (2004) 232-239
37. Berentsen S., Ulvestad E., Gjertsen B.T., et al. Rituximab for primary cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 103 (2004) 2925-2928
38. Iacona I., Lazzarino M., Avanzini M.A., et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 22 (2000) 295-301
39. Beum P.V., Kennedy A.D., and Taylor R.P. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukaemia and other B cell lymphomas. J Immunol Methods 289 (2004) 97-109
40. Cragg M.S., Bayne M.B., Tutt A.L., et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 104 (2004) 2540-2542
41. Hong K., Presta L.G., Lu Y., et al. Simple quantitative live cell and anti-idiotype antibody based ELISA for humanized antibody directed to cell surface protein CD20. J Immunol Methods 294 (2004) 189-197
42. Mangel J., Buckstein R., Imrie K., et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as "in vivo purge" and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 14 (2003) 758-765
43. Regazzi M.B., Iacona I., Avanzini M.A., et al. Pharmacokinetic behaviour of rituximab. A study of different schedules of administration for heterogenous clinical settings. Ther Drug Monit 27 (2005) 785-792
44. Scheidhauer K., Wolf I., Baumgartl H.J., et al. Biodistribution and kinetics of (131)I-labelled anti CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 29 (2002) 1276-1282
45. Tobinai K., Kobayashi Y., Narabayashi M., et al. Feasability and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol 9 (1998) 527-534
46. Dietlein M., Pels H., Schulz H., et al. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol 74 (2005) 348-352
47. Rubenstein J.L., Combs D., Rosenberg J., et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101 (2003) 466-468
48. Jillella A.P., Dainer P.M., Kallab A.M., et al. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. Am J Hematol 71 (2002) 219-222
49. Takao T., Kobayashi Y., Kuroda J., et al. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis. Am J Hematol 77 (2004) 419-420
50. Tokar M., Rogachev B., Levi I., Yerushalmi R., Ariad S., and Geffen D.B. Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys. Leuk Lymphoma 45 (2004) 819-820
51. Vieira C.A., Agarwal A., Book B.K., et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77 (2004) 542-548
52. Ng C.M., Bruno R., Combs D., and Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45 (2005) 792-801
53. Danhof M., Alvan G., Dahl S.G., Kuhlmann J., and Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res 22 September (9) (2005) 1432-1437
54. Manches O., Lui G., Chaperot L., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101 (2003) 949-954
55. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
56. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 November (21) (2003) 3940-3947
57. Miescher S., Spycher M.O., Amstutz H., et al. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. Blood 103 (2004) 4028-4035
58. Louis E., El Ghoul Z., Vermeire S., et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 19 (2004) 511-519
59. Dall'Ozzo S., Tartas S., Paintaud G., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64 (2004) 4664-4669
60. D'Arch C., and Mannik M. Serum sickness secondary to treatment with the murine human chimeric antibody IDEC C2B8. Arthritis Rheum 44 (2001) 1717-1718
61. Herishanu Y. Rituximab induced serum sickness. Am J Hematol 70 (2002) 329
62. Maeda T., Yamada Y., Tawara M., et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8 rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol 74 (2001) 70-75
63. Ternant D., and Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 5 (2005) S37-S47